- Home
- ANTA vs DTIL Comparison
ANTA vs DTIL Comparison
Compare ANTA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | DTIL |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | Singapore | United States |
| Employees | 113 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.1M | 185.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANTA | DTIL |
|---|---|---|
| Price | $6.65 | $6.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $16.17 | ★ $45.00 |
| AVG Volume (30 Days) | 1.8K | ★ 359.3K |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $30.46 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $3.53 |
| 52 Week High | $13.82 | $8.82 |
Technical Indicators
Market Signals| Indicator | ANTA | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 41.99 |
| Support Level | $6.80 | $5.32 |
| Resistance Level | $9.81 | $8.08 |
| Average True Range (ATR) | 0.34 | 0.62 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 23.64 | 13.06 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).